MARKET-DISCOVERED GROUP
Price direction is split across 9 measured members. Capital-flow confirmation is unavailable.
WED, FEB 18PTCT filing documented shared operating contextproduct pipeline / R&D affecting expense · date precision only
WED, AUG 5DNLI filing documented shared operating contextproduct pipeline / R&D affecting expense · date precision only
01 · WHAT IS HAPPENING
Observed intraday paths are not available for this group yet.
02 · WHY IT MATTERS
Moderate filing support: the strongest shared 10-Q/K outlook is operating setup (near-term outlook) across DNLI, EXEL, INCY, KNSA, KRYS, MIRM, NBIX, PRVA.
“The decrease was primarily due to decreases in royalty costs driven by Emflaza as a result of the completion of the royalty agreement with Marathon Pharmaceuticals, LLC (now known as Complete Pharma Holdings, LLC), which was partially offset by costs associated with the Novartis Agreement, inventory costs associated with the Sephience launch, Upstaza/Kebilidi and Sephience royalty payments, an increase in inventory reserves, and costs associated with new product sales.”
PTCT 10-K · 2026-02-19
“44 Table of Contents The increase in other hematology and oncology net sales for the three and six months ended June 30, 2026 as compared to the corresponding period in 2025 was primarily driven by increased demand of NIKTIMVO, MONJUVI/MINJUVI and ZYNYZ, reflecting continued strong uptake of these products in the U.S. and their entry into new markets outside of the U.S.”
INCY 10-Q · 2026-07-28
“The impairment was related to a decrease in projected cash flows due to refinements in current market assumptions and the timing of patient treatments.”
PTCT 10-K · 2026-02-19
No qualified cross-asset lead/lag link is available for this group.
Filing-linked outsiders test whether the move is spreading beyond the established cohort.
No high-confidence filing-linked outsiders are available for this group yet.
03 · WHO IS IN IT
4/9 active8 rising · 1 falling
| TICKER | Company | Role now | Today | Observed history | Trader interpretation |
|---|---|---|---|---|---|
| KNSA | Kiniksa Pharmaceuticals International, plc | Participating | +1.6% | — | Price participation is not yet confirmed by per-name flow. |
| PRVA | Privia Health Group, Inc. | Participating | -0.1% | — | Price participation is not yet confirmed by per-name flow. |
| KRYS | Krystal Biotech, Inc. | Participating | +3.0% | — | Price participation is not yet confirmed by per-name flow. |
| MIRM | Mirum Pharmaceuticals, Inc. | Participating | +1.6% | — | Price participation is not yet confirmed by per-name flow. |
| PTCT | PTC Therapeutics, Inc. | Most unusual | +1.4% | — | Most unusual activity in this snapshot; performance direction may differ. |
| INCY | Incyte Corporation | Participating | +4.0% | — | Price participation is not yet confirmed by per-name flow. |
| DNLI | Denali Therapeutics Inc. | Participating | +5.6% | — | Price participation is not yet confirmed by per-name flow. |
| EXEL | Exelixis, Inc. | Participating | +2.4% | — | Price participation is not yet confirmed by per-name flow. |
| NBIX | Neurocrine Biosciences, Inc. | Quiet / lagging | +0.8% | — | Not participating yet; a breadth test or a genuine divergence. |
04 · HAS THIS HAPPENED BEFORE
No completed point-in-time outcome is available yet. New live confirmations are now retained with their exact observation timestamp; statistics appear only after the corresponding candles complete.
Only 0 completed episodes across 0 active sessions; treat history as context, not a validated playbook. These episode counts describe recurrence; the outcome ledger above is the only forward-performance evidence.
Historical cohort observations are not available yet.